慢性腰痛に対するサイロシビン療法 (POP)
慢性腰痛患者に対するサイロシビン療法の予備的有効性を調べる二重盲検ランダム化試験
This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two preparation sessions, a dosing session, three integration sessions to discuss their psilocybin experience, and several follow up sessions.
調査の概要
状態
条件
詳細な説明
Chronic pain is associated with higher levels of pain-related distress, depression, emotional dysfunction, helplessness, hopelessness, and suicidality. Psilocybin is a psychoactive drug that may be well-suited to easing the psychological and emotional symptoms of distress associated with chronic pain. Previous studies testing psilocybin therapy have shown improvements on multiple behavioral and psychiatric outcomes, but it is unknown whether psilocybin therapy similarly enables patients to cope with chronic pain more effectively. The investigators will determine whether psilocybin therapy improves patients' ability to cope with chronic low back pain. If psilocybin therapy is an effective treatment in this population, its use could be incorporated into interventions for chronic low back pain and other psychological conditions.
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
San Francisco、California、アメリカ、94107
- University of California San Francisco
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 25 to 70 years old
- Comfortable speaking and writing in English
- Diagnosed with chronic low back pain
- Able to attend all in-person visits at UCSF as well as virtual visits
- Has tried at least two previous medications/ procedures and physical therapy trials for low back pain
Exclusion Criteria:
- Chronic low back pain that is attributed to malignancy, subacute or acute fracture or infection
- Low back pain with radiation below the knee
- Low back pain with neurologic signs present
- Regular use of medications that may have problematic interactions with psilocybin, including but not limited to dopamine agonists, MAO inhibitors, antipsychotics, and stimulants
- A health condition that makes study unsafe or unfeasible, determined by study physicians
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Psilocybin in combination with Zolpidem and Modafinil
Single dose of Psilocybin (1mg-30mg) in combination with zolpidem and modafinil |
1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
他の名前:
|
|
実験的:Psilocybin in combination with Zolpidem
Single dose of Psilocybin (1mg-30mg) in combination with zolpidem |
1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
他の名前:
|
|
実験的:Psilocybin in combination with Modafinil
Single dose of Psilocybin (1mg-30mg) in combination with modafinil |
1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
他の名前:
|
|
実験的:Psilocybin in combination with Placebo
Single dose of Psilocybin (1mg-30mg) in combination with placebo |
1-30 mg (oral administration), and placebo (oral administration)
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in pain interference
時間枠:Baseline, 1-month after psilocybin session
|
The Brief Pain Inventory-Interference subscale (BPI) will be used to assess how pain interferes with a variety of daily activities (e.g., walking, lifting, mood, sleep, relationships). Seven items are rated on a scale from 0 (does not interfere) to 10 (completely interferes) for a total possible score ranging from 0 to 70. Higher scores represent greater interference from pain. |
Baseline, 1-month after psilocybin session
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in pain interference
時間枠:Baseline, 1-week, and 3-months
|
The Brief Pain Inventory-Interference subscale (BPI) will be used to assess how pain interferes with a variety of daily activities (e.g., walking, lifting, mood, sleep, relationships). Seven items are rated on a scale from 0 (does not interfere) to 10 (completely interferes) for a total possible score ranging from 0 to 70. Higher scores represent greater interference from pain. |
Baseline, 1-week, and 3-months
|
|
Change in average pain intensity
時間枠:Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
The Brief Pain Inventory with the Michigan Body Map will be used to assess pain location and worst, least, average, and present pain on a numerical rating scale from 0 (no pain) to 10 (pain as bad as you can imagine) over the past 24 hours, where higher scores represent greater pain intensity. |
Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
|
Change in clinical depressive symptom severity
時間枠:Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
The 17-item clinician administered Hamilton Rating Scale for Depression will be used to assess changes in the severity of depressive symptoms. Each item is scored by a clinician on a 3- or 5-point scale from 0 (Not present) to 4 (severe) and summed for a total score between 0 and 52. A higher total score represents greater depressive symptom severity. |
Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
|
Change in depressive symptom severity
時間枠:Baseline, pre-dosing session, 5-days, 11-days, and 77-days after psilocybin session
|
The 7-item PROMIS-Depression self-report scale will be used as an additional indicator for changes in depression symptom severity. Items are endorsed on a 5-point scale ranging from 1 (Never) to 5 (Always). A higher total score represents greater depressive symptom severity. |
Baseline, pre-dosing session, 5-days, 11-days, and 77-days after psilocybin session
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Joshua Woolley、University of California, San Francisco
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。